Pricing Log in Create free account

Tarsus Pharmaceuticals, Inc. (TARS) vs Telix Pharmaceuticals Limited (TLX)

Tarsus Pharmaceuticals, Inc. and Telix Pharmaceuticals Limited are both Biotechnology companies. Tarsus Pharmaceuticals, Inc. and Telix Pharmaceuticals Limited are of similar size ($3.6B and $3.5B). Across the 8 metrics below, Tarsus Pharmaceuticals, Inc. leads on 6 and Telix Pharmaceuticals Limited on 2.

Valuation

Metric TARS TLX Biotechnology median
P/E n/m — 8.50
P/S 4.87 — 9.71
P/B 8.52 n/m 2.13
Price to free cash flow 62.84 n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 4.25 n/m 9.21
Earnings yield (1.60%) — (33.15%)
Free cash flow yield 1.59% 0.00% (25.50%)

Profitability

Metric TARS TLX Biotechnology median
Gross margin 93.28% — 65.16%
Operating margin (8.00%) — 0.00%
Net margin (7.67%) — 0.00%
Free cash flow margin 9.24% 0.00% 0.00%
Return on equity (13.68%) 0.00% (56.36%)
Return on assets (8.40%) 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric TARS TLX Biotechnology median
Revenue growth (TTM) 105.17% — 6.02%
EPS growth (last fiscal year) 48.21% (120.00%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric TARS TLX Biotechnology median
Debt to equity 0.21 1.18 0.00
Current ratio 3.20 2.01 4.72
Net debt to EBITDA 4.66 6.25 0.96

Dividend

Metric TARS TLX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric TARS TLX Biotechnology median
Market cap 3.50b 3.60b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack